The market for Vulvovaginal Candidiasis (VVC) was valued at USD 971.51 million in 2021 and is anticipated to grow at a 4.2% CAGR in terms of revenue during the projected period. The rise in vulvovaginal candidiasis infections in women around the world, rising regulatory approvals for vulvovaginal candidiasis treatments, and an increase in clinical research studies into vulvovaginal candidiasis treatments are key factors propelling this market's revenue growth.
The report focuses on current and future market growth, technological advancements, volume, raw materials, and profiles of the key companies involved in the market. The report provides valuable insights to the stakeholders, investors, product managers, marketing executives, and other industry professionals.
The global Vulvovaginal Candidiasis industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.
The leading market contenders listed in the report are:
Mycovia Pharmaceuticals, Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc, Cadila Pharmaceuticals., SCYNEXIS, Inc., Grupo Ferrer International S.A., Phathom Pharmaceuticals, Inc., and Lupin
Key market aspects studied in the report:
Market Scope: The report explains the scope of various commercial possibilities in the global Vulvovaginal Candidiasis market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.
Competitive Outlook: The leading companies operating in the Vulvovaginal Candidiasis market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.
Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Vulvovaginal Candidiasis market.
Market Segmentations of the Vulvovaginal Candidiasis Market
This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Vulvovaginal Candidiasis market on the basis of product, application, and region:
Segments Covered in this report are:
Drug Type Outlook (Revenue, USD Million; 2019-2030)
Clotrimazole
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others
Route of Administration Outlook (Revenue, USD Million; 2019-2030)
Oral
Topical
Intravenous
Distribution Channel Outlook (Revenue, USD Million; 2019-2030)
